Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Does Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease? (HIHA)

14. september 2026 oppdatert av: Jens Bansi, Klinik Valens

The goal of this pilot randomized controlled trial is to investigate the effects of hippotherapy (horse assisted therapy) (intervention group) compared to usual care (control group) on mobility, gait, balance and perceived health-related quality of life in persons with Parkinson's disease. The main objectives of this study are:

  • The primary objective is to investigate the effects of hippotherapy on mobility of pwPD, walking speed and the ability to perform daily movements.
  • The secondary objective is to investigate the effects of hippotherapy on (a) balance, (b) self-perceived physical and mental health and (c) specific gait parameters.
  • Furthermore this study, aims to gather critical information that will inform about the design and implementation of a larger, more definitive randomized controlled trial.

In addition to the three-week, multidisciplinary rehabilitation program the intervention group will receive hippotherapy (20 minutes) three times a week (7 sessions in total) and the control group will receive additional physiotherapy sessions (30 minutes) two times a week.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Sveits
    • Canton of St. Gallen
      • Valens, Canton of St. Gallen, Sveits, 7317
        • Rekruttering
        • Rehabilitation Centre Valens
        • Hovedetterforsker:
          • Jens Bansi, PhD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Confirmed diagnosis of Parkinson's diagnosis
  • Age > 18 Years;
  • Hoehn & Yahr stage ≤ 4;
  • Category 3 in the Functional Ambulation Categories
  • Climbing stairs is possible (with support).

Exclusion Criteria:

  • Severe cognitive impairment, defined by a score below 26 on the Montreal Cognitive Assessment (MoCa)
  • Body weight > 90kg;
  • Horse hair allergy;
  • Other acute and subacute cardiovascular, respiratory, musculoskeletal or neurological disorders that constitute a contraindication to hippotherapy (i.e. a recent fracture);
  • Pregnancy.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Hippotherapy
In addition to the three-week, multidisciplinary rehabilitation program the intervention group will receive hippotherapy three times a week (7 sessions in total). The hippotherapy sessions last 20 minutes each and aim at trunk rotation (in the transverse and frontal plane), rhythm and trunk stability. They will receive this in addition to the usual three-week rehabilitation program. This program includes 30 minutes of physical therapy daily plus two additional physiotherapy sessions of 30 minutes, 30 minutes of occupational therapy 3x/week, strength training 3x/week, 45 minutes of balance training 2x/week and, as required, other therapies such as nutritional advice, speech therapy and/or creative therapy to meet the individual needs of people with Parkinson's.
Annen: Hippotherapy
Hippotherapy is a form of physical therapy that utilizes the natural gait and movement of a horse to provide motor and sensory input. The hippotherapy sessions last 20 minutes each and aim at trunk rotation (in the transverse and frontal plane), rhythm and trunk stability.
Andre navn:
  • Equine assisted therapy
Aktiv komparator: Usual care
The comparison group will perform the three-week rehabilitation program, without hippotherapy. This program includes 30 minutes of physical therapy daily plus two additional physiotherapy sessions of 30 minutes, 30 minutes of occupational therapy 3x/week, strength training 3x/week, 45 minutes of balance training 2x/week and, as required, other therapies such as nutritional advice, speech therapy and/or creative therapy to meet the individual needs of people with Parkinson's.
Annen: Physiotherapy
Physiotherapy sessions take 30 minutes and focus on core stability and exercises with large motor tasks
Andre navn:
  • Treningsterapi
  • Fysioterapi

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Functional mobility.
Tidsramme: From enrollment to the end of treatment at 3 weeks

Functional mobility will be measured with the expanded Timed Up and Go test.

The eTUG is a modification of the traditional Timed Up and Go test, whereby the distance is increased from 6 to 10m. This has enabled a more accurate gait assessment in pwPD. Multiple time points are assessed:

  • The time the person takes to get from a sitting to standing position.
  • The time the person takes to walk the first two meters (gait initiation)
  • The time the person takes to walk the remaining (gait 1)
  • The time the person takes to turn (turning)
  • The time the person takes to (gait 2)
  • The time the person takes to slow down, turn and sit down again

The more time someone takes to perform the test, the more the mobility is impaired.
From enrollment to the end of treatment at 3 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Balance
Tidsramme: From enrollment to the end of treatment at 3 weeks
Balance will be assessed with the Mini Balance Evaluation Systems Test (Mini-BESTest). The Mini-BESTest is shorter, more clinically applicable version of the original Balance Evaluation Systems Test (BESTest). This test focuses on subcomponents of balance control, such as anticipatory postural adjustments, postural responses, sensory orientation, and dynamic gait. It has proven to be effective in detecting balance impairments in persons with Parkinsons disease. The scale ranges from 0-28 points, with higher scores indicating better balance capacity.
From enrollment to the end of treatment at 3 weeks
Health related quality of life
Tidsramme: From enrollment to the end of treatment at 3 weeks
Health related quality of life will be assessed with the Patient-Reported Outcomes Measurement Information System Global Health Short Form v1.2 (PROMIS-GH-10). The PROMIS-GH-10 is a ten-item questionnaire that assesses generic health related quality of life compared with normal values for the general population. It measures five domains: physical function, fatigue, pain, emotional distress, and social health on a five-point response matrix. Both physical and mental scores range from 0-20, with higher scores indicating a better perceived health related quality of life.
From enrollment to the end of treatment at 3 weeks
Walking capacity
Tidsramme: From enrollment to the end of treatment at 3 weeks
Walking capacity will be tested using the 6 minutes walking test (6-MWT). With the 6-MWT, the total distance in meters covered within six minutes is assessed. The 6-MWT is performed on a 20-meter hallway, on which participants are asked to walk back and forth at maximal speed for the duration of six minutes without permission of rest. The instruction is standardized as "to walk at the fastest speed, and to cover as much distance as possible". Participants are allowed to use a walking aid, if necessary to ensure safe ambulation. The use of walking aids will be documented in the CRF, and participants are asked to use the same walking aid during the re-test at T1. During the tests, the research assistant blinded to group allocation is instructed, to not encourage the participant. The greater the distance walked during the test, the greater the walking endurance.
From enrollment to the end of treatment at 3 weeks

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Adherence
Tidsramme: From enrollment to the end of treatment at 3 weeks
Adherence rates will be obtained to help design and implement a larger scaled randomized controlled trial. The therapist that is performing the hippotherapy or additional physiotherapy sessions with the participant will document the training in the CRF. This includes reasons for not coming to the session (i.e. no motivation, falling sick, etc), reasons for early termination of the training session (i.e. fear, difficulty climbing on the horse) and a free space to write any other relevant information.
From enrollment to the end of treatment at 3 weeks
Recruitment rates
Tidsramme: through study completion, approximately 2 years.
Recruitment rates will be obtained to gather information that will help to design and implement a larger scaled randomized controlled trial. The research assistant that is responsible for recruitment will keep a list that keeps track of the date of recruitment / exclusion and reason of exclusion (i.e. does not want to participate, does not meet the inclusion criteria).
through study completion, approximately 2 years.
Adverse effects.
Tidsramme: From enrollment to the end of treatment at 3 weeks

Adverse effects concern the documentation of:

  • reasons for study withdrawal (drop-out),
  • reasons for incomplete session attendance (< 7 session)
  • reasons for session abortion
  • reasons for deviations from exercise prescription
  • sudden severe disease progression or falling sick (e.g., bacterial or viral infections) during the study (discontinuation criterion)
From enrollment to the end of treatment at 3 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Klinik Valens

Samarbeidspartnere

Schweizer Gruppe für Hippotherapie-K

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. januar 2025

Primær fullføring (Antatt)

1. januar 2027

Studiet fullført (Antatt)

1. januar 2027

Datoer for studieregistrering

Først innsendt

31. august 2026

Først innsendt som oppfylte QC-kriteriene

31. august 2026

Først lagt ut (Faktiske)

3. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. september 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • Hippo-HIHA

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere